Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Share-based Compensation (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Share-based Compensation for 4 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 5.24% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2025, up 80.07% year-over-year, with the annual reading at $12.0 million for FY2025, 12.84% up from the prior year.
  • Share-based Compensation for Q4 2025 was $2.8 million at Orchestra BioMed Holdings, down from $3.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $3.2 million in Q2 2025, with the low at $30000.0 in Q3 2022.
  • Average Share-based Compensation over 4 years is $1.4 million, with a median of $968500.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 2027.14% in 2023, then crashed 46.67% in 2024.
  • Over 4 years, Share-based Compensation stood at $863000.0 in 2022, then rose by 6.49% to $919000.0 in 2023, then surged by 215.78% to $2.9 million in 2024, then dropped by 5.24% to $2.8 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.8 million, $3.0 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.